Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach

Table 1 Trials showing benefits of finerenone in diabetes kidney disease

Trial name	No of Subjects (T2DM on maximally tolerated ACEi/ARB)	Follow up	Renal outcomes (kidney failure, more than 40 percentage decrease in eGFR from baseline, or renal death)	CV outcome (cardiovascular death, nonfatal MI, nonfatal stroke, or heart failure hospitalization)	Reduction of UACR from baseline to month 4
FIDELIO-DKD[20]	5734	2.6 years	17.8 percentage with finerenone vs 21.1 percentage with placebo (HR = 0.82, 95%CI: 0.73-0.93; P = 0.001)	13.0 percentage with finerenone vs 14.8 percentage with placebo (HR = 0.86, 95%CI: 0.75-0.99; P = 0.03)	31% greater reduction than placebo [ratio of least-squares mean change from baseline (finerenone vs placebo), 0.69; 95%CI: 0.66-0.71]
FIGARO-DKD[21]	7437	3.4 years	9.5 percentage with finerenone vs 10.8 percentage with placebo (HR = 0.87, 95%CI: 0.76-1.01; P = 0.07)	12.4 percentage with finerenone vs 14.2 percentage with placebo (HR = 0.87, 95%CI: 0.76-0.98; P = 0.03)	32% greater reduction with finerenone than with placebo (ratio of the least-squares mean change from baseline, 0.68; 95%CI: 0.65-0.70)

ACEi: Angiotensin convertase enzyme inhibitor; ARB: Angiotensin receptor blocker; CV: Cardiovascular; eGFR: Estimated glomerular filtration rate; HR: Hazards ratio; MI: Myocardial infarction; T2DM: Type 2 diabetes mellitus.